CTOs on the Move

Dermatologists of Central States

www.docsdermgroup.com

 
DOCS Dermatologists of Central States is one of the largest dermatology practice groups in the United States. With over 155 providers spread across seven central states, we have been serving patients for over 40 years. Our focus is on medical, surgical...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Jesse Fatherree
Director of IT Operations Profile

Similar Companies

ICS Connect

ICS Connect is a Frisco, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clinical Professionals

Clinical Professionals is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Golo

GOLO is a pioneering wellness solutions company that empowers individuals by helping them take control of their personal health. The company provides safe and effective solutions for weight loss and wellness while helping customers transition to a healthier and sustainable lifestyle. To date, GOLO has reached over two million people worldwide who now have a chance at a healthier life.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.

Anthem Incorporated

At Anthem, Inc., we believe that our health connects us all. So we focus on being a valued health partner and delivering quality products and services that give members access to the care they need. With more than 67 million people served by our affiliated companies including approximately 37 million enrolled in our family of health plans, we can make a real difference to meet the needs of our diverse customers.